Multiple myeloma;Das multiple MyelomZu

Internist

Volumn 54, Issue 8, 2013, Pages 963-977

  Kortum K M ^a   Engelhardt, M ^b,c   Rasche, L ^c   Knop, S ^c   Einsele, H ^c  

^a MAYO CLINIC   (United States)

^b UNIVERSITY OF FREIBURG   (Germany)

^c UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

Author keywords

Bone marrow examination; Classification; Cyclophosphamide; Melphalan; Monoclonal gammopathy of undetermined significance

Indexed keywords

BORTEZOMIB; CYCLOPHOSPHAMIDE; LENALIDOMIDE; MELPHALAN; THALIDOMIDE; ALKYLATING AGENT;

ARTICLE; B LYMPHOCYTE; BLOOD CELL COUNT; BONE MARROW BIOPSY; CANCER CHEMOTHERAPY; HUMAN; KIDNEY FUNCTION; MONOCLONAL IMMUNOGLOBULINEMIA; MULTIPLE MYELOMA; NONHODGKIN LYMPHOMA; PLASMA CELL; URINALYSIS; IMMUNOLOGY;

ANTINEOPLASTIC AGENTS, ALKYLATING; CYCLOPHOSPHAMIDE; HUMANS; MELPHALAN; MULTIPLE MYELOMA;

EID: 84888002703     PISSN: 00209554     EISSN: 14321289     Source Type: Journal    
DOI: 10.1007/s00108-013-3336-2     Document Type: Article

References (35)

1. Katalinic A, Pritzkuleit R (2013) Hochrechnung des Instituts für Krebsepidemiologie e. V., Lübeck für ICD-10: C90 auf Basis der Daten der Krebsregister BY, BR, HB, HH, MV, NI, NW (Reg.-bez. Münster), SL, SN, SH (2005-2009) mit einer Bezugsbevölkerung von etwa 38 Mio. Menschen (46% der Gesamtbevölkerung), nähere Angaben zur Methodik s. auch http://www.gekid.de
2. Greenberg AJ, Vachon CM, Rajkumar SV (2012) Disparities in the prevalence, pathogenesis and progression of monoclonal gammopathy of undetermined significance and multiple myeloma between blacks and whites. Leukemia 26:609-614
3. Landgren O, Kyle RA, Pfeiffer RM et al (2009) Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study. Blood 113:5412-5417
4. Weiss BM, Abadie J, Verma P et al (2009) A monoclonal gammopathy precedes multiple myeloma in most patients. Blood 113:5418-5422
5. International Myeloma Working Group (2003) Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. Br J Haematol 121:749-757
6. Eisele L, Durig J, Huttmann A et al (2012) Prevalence and progression of monoclonal gammopathy of undetermined significance and light-chain MGUS in Germany. Ann Hematol 91:243-248
7. Rajkumar SV, Kyle RA, Buadi FK (2010) Advances in the diagnosis, classification, risk stratification, and management of monoclonal gammopathy of undetermined significance: implications for recategorizing disease entities in the presence of evolving scientific evidence. Mayo Clin Proc 85:945-948
8. Dispenzieri A, Katzmann JA, Kyle RA et al (2010) Prevalence and risk of progression of light-chain monoclonal gammopathy of undetermined significance: a retrospective population-based cohort study. Lancet 375:1721-1728
9. Kyle RA, Therneau TM, Rajkumar SV et al (2002) A long-term study of prognosis in monoclonal gammopathy of undetermined significance. N Engl J Med 346:564-569
10. Zingone A, Kuehl WM (2011) Pathogenesis of monoclonal gammopathy of undetermined significance and progression to multiple myeloma. Semin Hematol 48:4-12
11. Kyle RA, Therneau TM, Rajkumar SV et al (2003) Long-term follow-up of IgM monoclonal gammopathy of undetermined significance. Blood 102:3759-3764
12. Kyle RA, Durie BG, Rajkumar SV et al (2010) Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management. Leukemia 24:1121-1127
13. Berenson JR, Anderson KC, Audell RA et al (2010) Monoclonal gammopathy of undetermined significance: a consensus statement. Br J Haematol 150:28-38
14. Merlini G, Stone MJ (2006) Dangerous small B-cell clones. Blood 108:2520-2530
15. Leung N, Bridoux F, Hutchison CA et al (2012) Monoclonal gammopathy of renal significance: when MGUS is no longer undetermined or insignificant. Blood 120:4292-4295
16. Weber D, Rankin K, Gavino M et al (2003) Thalidomide alone or with dexamethasone for previously untreated multiple myeloma. J Clin Oncol 21:16-19
17. Kyle RA, Gertz MA, Witzig TE et al (2003) Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin Proc 78:21-33
18. Blade J, Fernandez de Larrea C, Rosinol L et al (2011) Soft-tissue plasmacytomas in multiple myeloma: incidence, mechanisms of extramedullary spread, and treatment approach. J Clin Oncol 29:3805-3812
19. Dimopoulos MA, Moulopoulos LA, Maniatis A et al (2000) Solitary plasmacytoma of bone and asymptomatic multiple myeloma. Blood 96:2037-2044
20. Dispenzieri A (2011) POEMS syndrome: 2011 update on diagnosis, risk-stratification, and management. Am J Hematol 86:591-601
21. Greipp PR, San Miguel J, Durie BG et al (2005) International staging system for multiple myeloma. J Clin Oncol 23:3412-3420
22. Fonseca R, Bergsagel PL, Drach J et al (2009) International Myeloma Working Group molecular classification of multiple myeloma: spotlight review. Leukemia 23:2210-2221
23. Egan JB, Shi CX, Tembe W et al (2012) Whole-genome sequencing of multiple myeloma from diagnosis to plasma cell leukemia reveals genomic initiating events, evolution, and clonal tides. Blood 120:1060-1066
24. Keats JJ, Chesi M, Egan JB et al (2012) Clonal competition with alternating dominance in multiple myeloma. Blood 120:1067-1076
25. Barlogie B, Anaissie E, Rhee F van et al (2007) Incorporating bortezomib into upfront treatment for multiple myeloma: early results of total therapy 3. Br J Haematol 138:176-185
26. Attal M, Harousseau JL, Facon T et al (2003) Single versus double autologous stem-cell transplantation for multiple myeloma. N Engl J Med 349:2495-2502
27. Cavo M, Tosi P, Zamagni E et al (2007) Prospective, randomized study of single compared with double autologous stem-cell transplantation for multiple myeloma: Bologna 96 clinical study. J Clin Oncol 25:2434-2441
28. McCarthy PL (2013) Part I: the role of maintenance therapy in patients with multiple myeloma undergoing autologous hematopoietic stem cell transplantation. J Natl Compr Canc Netw 11:35-42
29. Einsele H, Schafer HJ, Hebart H et al (2003) Follow-up of patients with progressive multiple myeloma undergoing allografts after reduced-intensity conditioning. Br J Haematol 121:411-418
30. Rosinol L, Perez-Simon JA, Sureda A et al (2008) A prospective PETHEMA study of tandem autologous transplantation versus autograft followed by reduced-intensity conditioning allogeneic transplantation in newly diagnosed multiple myeloma. Blood 112:3591-3593
31. Zeiser R, Deschler B, Bertz H et al (2004) Extramedullary vs medullary relapse after autologous or allogeneic hematopoietic stem cell transplantation (HSCT) in multiple myeloma (MM) and its correlation to clinical outcome. Bone Marrow Transplant 34:1057-1065
32. Dimopoulos MA, Kastritis E, Rosinol L et al (2008) Pathogenesis and treatment of renal failure in multiple myeloma. Leukemia 22:1485-1493
33. Durie BG, Harousseau JL, Miguel JS et al (2006) International uniform response criteria for multiple myeloma. Leukemia 20:1467-1473
34. (o A) (2013) MM-Pathway, Version 3, 6/2013. Das Blaue Buch, 5. Aufl. Springer (in Vorbereitung)
35. Terpos E, Roodman GD, Dimopoulos MA (2013) Optimal use of bisphosphonates in patients with multiple myeloma. Blood 121:3325-3328